Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C
Überleben und Komplikationen bei kanadischen Kindern mit Retinoblastom: populationsbasierter Bericht aus CYP-C
Pediatric Blood & Cancer · 2026-07 · 73 (7)
DOI: 10.1002/1545-5017.70316 ↗Auf einen Blick
In einer nationalen Kohorte von 484 Kindern mit Retinoblastom lag das 5-Jahres-Überleben bei 94,2 %. Metastatische Erkrankung und nicht-weiße Ethnie waren mit geringerem Überleben verbunden.
Fragestellung
Beschreibung des Überlebens und der Prädiktoren für Tod und Komplikationen bei kanadischen Kindern mit Retinoblastom.
Methode
Retrospektive populationsbasierte Kohortenstudie mit Daten aus der Cancer in Young People in Canada-Datenbank; Diagnosejahre 2001 bis 2019.
Ergebnisse
484 Patient:innen; Medianalter bei Diagnose 1,2 Jahre (IQR 0,4–2,2). 5-Jahres-OS 94,2 % (95 %-KI 90,8–96,3). Metastasen: 12,5 % vs. 96,2 %; nicht-weiß: 88,8 % vs. 96,3 %.
Schlussfolgerung der Autor:innen
Die Studie berichtete wenige Komplikationen bei Kindern mit Retinoblastom, zeigte aber relevante Überlebensunterschiede bei nicht-weißen Patient:innen und bei metastatischer Erkrankung.
Kernaussagen
- 5-Jahres-OS: 94,2 % (95 %-KI 90,8–96,3)
- Metastatische Erkrankung mit geringerem 5-Jahres-OS
- Grade 3–4-Komplikationen bei 4,8 % der Kohorte
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.04.2026. Verfasst von Samuel Sassine und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Retinoblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Garron Family Cancer Centre Fellowship, Charles-Bruneau Fellowship, Empowering Next-generation Researchers In perinatal and Child Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Methods
We performed a retrospective, population‐based cohort study using the Cancer in Young People in Canada database of all children diagnosed with RB from 2001 to 2019. Primary outcomes were 5‐year overall survival (OS) and grade 3–4 complications. Univariate and multivariable regression analyses were performed to assess associations between clinical characteristics and the outcomes. Kaplan–Meier survival analyses were conducted to estimate time‐to‐event outcomes.
Results
Among the 484 patients, the median age at diagnosis was 1.2 years (interquartile range: 0.4–2.2). Eight (1.7%) patients had metastatic disease at diagnosis, and 273 (56.4%) underwent enucleation. Overall, 96.1% of patients in the cohort were alive at last follow‐up. The cohort's 5‐year OS, as estimated by the Kaplan–Meier method, was 94.2% (95% CI 90.8–96.3). Compared with localized disease, metastatic disease was associated with inferior 5‐year OS (12.5% vs. 96.2%, p < 0.001). Non‐White patients (vs. White patients) had inferior 5‐year OS (88.8% vs. 96.3%, p = 0.003). The prevalence of grade 3 and 4 complications was 4.8% across the entire cohort ( n = 31 events, n = 23 patients). Eight (1.7%) patients developed grade 3 or 4 hearing loss.
Conclusion
This large population‐based study reported few complications in children with RB but highlighted key survival disparities among non‐White patients and patients with metastatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Quebec, Canada.
- CHU Sainte-Justine Azrieli Research Center, Montreal, Quebec, Canada.
- Division of Ophthalmology, CHU Sainte-Justine, Montreal, Quebec, Canada.
- Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Samuel Sassine
Förderung
- Garron Family Cancer Centre Fellowship
- Charles-Bruneau Fellowship
- Empowering Next-generation Researchers In perinatal and Child Health
- Brain Tumour Foundation of Canada Feature Grant
- Public Health Agency of Canada
Zitieren
APA
Sassine, S., Trudeau-Ferrin, O., Laverdière, C., Hamel, P., Superstein, R., Koukoui, B., Provost, C., Nathan, P. C., Ramaswamy, V., Shaikh, F., Gallie, B., Mallipatna, A., Kletke, S., Dimaras, H., & Coltin, H. (2026). Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70316
Vancouver
Sassine S, Trudeau-Ferrin O, Laverdière C, Hamel P, Superstein R, Koukoui B, et al. Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70316
BibTeX
@article{Sassine2026,
author = {Sassine, Samuel and Trudeau-Ferrin, Ofélie and Laverdière, Caroline and Hamel, Patrick and Superstein, Rosanne and Koukoui, Bénédicte and Provost, Carole and Nathan, Paul C and Ramaswamy, Vijay and Shaikh, Furqan and Gallie, Brenda and Mallipatna, Ashwin and Kletke, Stephanie and Dimaras, Helen and Coltin, Hallie},
title = {Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {7},
doi = {10.1002/1545-5017.70316}
}
EUVIMED